|
|
Volumn , Issue , 2013, Pages 301-305
|
|
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms
a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
11-(2-PYRROLIDIN-1-YLETHOXY)-14,19-DIOXA-5,7,26-TRIAZATETRACYCLO(19.3.1.1(2,6).1(8,12))HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE;
BENZAMIDE DERIVATIVE;
BRIDGED COMPOUND;
FEDRATINIB;
JAK1 PROTEIN, HUMAN;
JAK2 PROTEIN, HUMAN;
JANUS KINASE 1;
JANUS KINASE 2;
N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE;
PROTEIN KINASE INHIBITOR;
PYRAZOLE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
PYRROLIDINE DERIVATIVE;
RUXOLITINIB;
SULFONAMIDE;
ANTAGONISTS AND INHIBITORS;
GENETICS;
HUMAN;
MOLECULARLY TARGETED THERAPY;
MORTALITY;
MUTATION;
MYELOPROLIFERATIVE DISORDERS;
PROCEDURES;
BENZAMIDES;
BRIDGED COMPOUNDS;
HUMANS;
JANUS KINASE 1;
JANUS KINASE 2;
MOLECULAR TARGETED THERAPY;
MUTATION;
MYELOPROLIFERATIVE DISORDERS;
PROTEIN KINASE INHIBITORS;
PYRAZOLES;
PYRIMIDINES;
PYRROLIDINES;
SULFONAMIDES;
|
|
EID: 84900465166
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.1200/EdBook_AM.2013.33.301 Document Type: Review |
|
Times cited : (7)
|
|
References (0)
|